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Introduction: The main cause of acute kidney injury (AKI) is ischemia/
reperfusion (IR). AKI has been associated with chronic kidney disease pro-
gression and cardiac alterations. Previous studies showed that in a rat model
of kidney IR, mineralocorticoid receptor (MR) antagonism with spironolac-
tone prevents tubular injury and renal dysfunction. Despite their benefits in
renal diseases, the current MR antagonists have strong limitations like hyper-
kalemia, thus motivating the search of novel antagonists with safer profile.
Objective: Test the efficacy of the non-steroidal MR antagonist BR-4628
against renal injury induced by IR.
Methods: Twenty male wistar rats were divided in 4 groups: sham-operated
(S), bilateral renal ischemia (IR) for 25min, treated with BR-4628 (10mg/kg)
either 3 days before IR (B10-pre) or 3 hours after IR (B10-post). All groups
were studied 24h after reperfusion. Blood sample was taken for creatinine and
urea quantification. The right kidney was processed for molecular studies and
the left for histopathological analysis.
Results: Rats with IR developed renal injury characterized by renal dys-
function, increase in tubular injury markers (Hsp72 and Kim-1), oxidized pro-
teins and pro-inflammatory cytokines. These alterations were absent in the
B10-pre and B10-post IR groups. IR induced an increased expression of the
M1 macrophage markers iNOS, CCL3, TNF-alpha and MCP-1 (inflammatory
phenotype) that was fully prevented with the BR-4628 pre-treatment. Further-
more we observed that in the B10-pre and B10-post groups there was a greater
expression of M2 macrophage markers; IL4r, FIZZ1 and Igfr2 (wound healing
phenotype), as compared to the non-treated IR group.
Conclusion: We show for the first time that the non-steroidal BR-4628
MR antagonist is effective to prevent or treat renal injury induced by IR pos-
sibly through a mechanism involving macrophage polarization towards the
wound healing phenotype.
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Intermittent hypoxia (IH), a major component of obstructive sleep apnea
syndrome (OSA), causes several cardiovascular alterations such as hyperten-
sion, increased infarct size and ventricular arrhythmias. Indeed, IH exposure
enhances the incidence of severe ventricular arrhythmias during both ischemia
and reperfusion. Oxidative stress is a common feature behind the deleterious
effects of both IH and ischemia-reperfusion on the myocardium. Zinc is an
essential metal associated with numerous proteins and playing a vital role in
various cellular functions. Its homeostasis is closely linked to the cell redox
state since zinc release by oxidation can induce protein conformation changes.
The resulting modification in protein activity could thus be restored by zinc
administration.
Thereby, the effects of zinc supplementation were investigated in isolated
perfused rat hearts presenting severe ventricular reperfusion arrhythmias fol-
lowing a 15-min regional ischemia. Incidence, severity and duration of ven-
tricular arrhythmias were assessed during the first 10min of reperfusion. Three
groups were compared in which zinc (pyrithione form, Zn-Pyr, 2.10-5M in
DMSO), DMSO (vehicle) or pyrithione sodium (Na-Pyr) was added to the
Krebs upon reperfusion. Reperfusion with Zn-Pyr significantly enhanced sur-
vival (40%) compared to DMSO or Na-Pyr (6%) (n=17 per group, p<0.05).
Moreover, the time spent in sinus rhythm was significantly increased in the
Zn-Pyr group compared to other groups (p<0.01). Accordingly, the duration of
ventricular tachycardia/fibrillation was significantly decreased in the Zn-Pyr
group (p<0.05).
Therefore, zinc administration during reperfusion improves survival in
response to a severe ischemic insult. Zinc supplementation upon myocardial
reperfusion procedures could thus represent a valuable approach to prevent the
occurrence of arrhythmias and could be of interest in the prevention of IH-
and OSA-related ventricular arrhythmias.
